tbuckley/cabot-search huggingface dataset:
AB1305 Risk of autoimmune rheumatic diseases in patients with palindromic rheumatism: a nationwide, population-based, cohort study
Authors: H.-H. Chen, W.-C. Chao, T.-L. Liao, C.-H. Lin, D.-Y. Chen
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Although the association between palindromic rheumatism (PR) and rheumatoid arthritis (RA) development has been widely reported, no research has estimated the magnitude of the risk of progression of PR to RA or to other autoimmue rheumatic diseases, such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjogren's syndrome (SS), dermatomyositis (DM) and polymyositis (PM). <h3>Objectives</h3> This study aimed to examine the relative risk of development of RA, SLE, SSc, SS, DM, or PM among patients with PR compared with that in non-PR individuals using a nationwide, population-based, administrative dataset. <h3>Methods</h3> The study utilised 2003–2013 claims data from the Taiwanese National Health Insurance Research Database. We identified 4421 cases of PR from 2007 to 2012 and randomly chose 44 210 non-PR individuals who matched (1:10) for age, sex and the year of index date without prior history of RA, SLE, SSc, SS, DM, or PM. After adjusting for age, sex, and the Charlson comorbidity index, we calculated the hazard ratios (HRs) with 95% confidence intervals (CIs) using the Cox proportional hazard model to quantify the risk of RA, SLE, SS, DM and PM in PR patients compared with that in matched non-PR individuals. <h3>Results</h3> Tthe mean age ±SD was 46±15 years, and 70.4% of the study subjects were female. The proportion of patients with one or more CCI was higher in the PR group than in the non-PR group (33.0% vs. 14.8%, p&lt;0.001). Among the 4421 patients with PR, 569 (12.87%) developed RA, 269 (6.08%) developed SS, 113 (2.56%) developed SLE, 5 (0.11%) developed SSc, 8 (0.18%) developed PM, and 1 (0.02%) developed DM. After adjusting for potential confounders, the patients with PR had an increased risk of RA (HR, 118.76; 95% CI, 89.81–157.04), SS (HR, 59.57; 95% CI, 43.87–80.88), SLE (HR, 51.56; 95% CI, 32.96–80.66) PM (HR, 57.38; 95% CI, 6.90–476.83), and SSc (HR, 13.42; 95% CI, 3.79–47.55) but not of DM (HR, 3.44; 95% CI, 0.34–34.59). <h3>Conclusions</h3> Patients with PR had an increased risk of developing RA, SS, SLE, PM, and SSc. <h3>References</h3> [1] Gonzalez-Lopez L, Gamez-Nava JI, Jhangri GS, Ramos-Remus C, Russell AS, Suarez-Almazor ME. Prognostic factors for the development of rheumatoid arthritis and other connective tissue diseases in patients with palindromic rheumatism. The Journal of rheumatology. 1999;26(3):540–5. PubMed PMID: 10090159. [2] Sanmarti R, Canete JD, Salvador G. Palindromic rheumatism and other relapsing arthritis. Best practice &amp; research Clinical rheumatology. 2004;18(5):647–61. doi: 10.1016/j.berh.2004.05.005. PubMed PMID: 15454124. <h3>Acknowledgements</h3> The authors would like to thank the Biostatistics Task Force of Taichung Veterans General Hospital, Taichung, Taiwan, ROC for statistical support. <h3>Disclosure of Interest</h3> None declared
THU0688 Do certain dmards increase risk of new-onset type 2 diabetes? evaluation of patients’ baseline characteristics
Authors: E. Alemao, Z. Guo, L. Ferri, L. Burns
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The risk of cardiovascular morbidities is higher in patients (pts) with RA and is exacerbated with type 2 diabetes (T2D).<sup>1</sup> Recent analysis showed that abatacept (ABA), a biologic (b)DMARD, has a lower incidence of T2D in pts with RA in clinical practice.<sup>2</sup> <h3>Objectives</h3> To compare baseline characteristics of pts with RA on DMARDs and evaluate incidence of T2D among these pts based on DMARD exposure. <h3>Methods</h3> Administrative claims data (2006–2016) from Optum Clinformatics (database A), QuintilesIMS PharMetrics Plus (database B) and Truven MarketScan<sup>®</sup> (database C). Inclusion criteria were: 2 RA diagnosis codes+1 DMARD prescription; age ≥18 years;≥3 months baseline (pre-index date); and 3 months of follow-up (post-index date). Mutually exclusive treatment groups (grp) were created based on the first prescription (index date) using a hierarchy of ABA, non-ABA bDMARDs (TNF inhibitors [TNFi] and non-TNFi [excluding ABA]) and conventional DMARDs (cDMARD; MTX or hydroxychloroquine [HCQ]). Also, an RA grp without DMARD use (NoDMARD) was identified. The index date for NoDMARD was first diagnosis date. Incident T2D was identified as those without T2D prior to index using one International Classification of Disease (ICD)−9 or ICD-10 diagnosis code for T2D. Assessment of T2D risk between treatment grps was based on regression and disease risk score (DRS) models. Adjusted incidence rate for T2D was based on a Cox model (stratified by DRS grps and categorised into 4 equal grps using quartile scores) with treatment as the independent variable. <h3>Results</h3> In databases A, B and C, 84,875, 2 07 811 and 1 94 819 pts with RA were identified, respectively (table 1). The combined proportions of pts in each treatment grp were: 3%–4% ABA; 12%–16% non-ABA bDMARD; and 41%–45% cDMARDs. Pts treated with ABA were older compared with those on non-ABA bDMARDs and a greater proportion had T2D risk factors of obesity, hypertension, dyslipidaemia and heart failure (table 1). The adjusted hazard ratios for T2D were significantly higher for non-bDMARD grps of TNFi and other bDMARDs vs ABA (figure 1). All data are% unless indicated otherwise (HR&gt;1 favours abatacept, HR&lt;1 favours other therapies) <h3>Conclusions</h3> Pts with RA treated with abatacept had greater risk factors for T2D at baseline. However, the adjusted risk of new-onset T2D was lower among abatacept pts versus other bDMARDs. <h3>References</h3> [1] Solomon DH, et al. Arthritis Rheum2004;50:3444–9. [2] Ozen G, et al. Ann Rheum Dis2017;76:848–54. <h3>Disclosure of Interest</h3> E. Alemao Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Z. Guo Employee of: Bristol-Myers Squibb, L. Ferri Employee of: Bristol-Myers Squibb, L. Burns Employee of: Bristol-Myers Squibb
Optimizing Mechanisms for Induction of Immunogenic Cell Death to Improve Patient Outcome in Multiple Myeloma
Authors: Annamaria Gulla, Eugenio Morelli, Teru Hideshima, Mehmet Kemal Samur, Giada Bianchi, Mariateresa Fulciniti, Nikhil Munshi, Kenneth C. Anderson
Journal: Blood (2018)
Rejection of adoptively transferred Eµ-TCL1 chronic lymphocytic leukemia cells in C57BL/6 substrains or knockout mouse lines
Authors: Selcen Öztürk, Philipp M. Roessner, Lena Schulze-Edinghausen, Haniyeh Yazdanparast, Verena Kalter, Peter Lichter, Bola S. Hanna, Martina Seiffert
Journal: Leukemia (2019)
Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder
Authors: Gihyun Yoon, Ismene L. Petrakis, John H. Krystal
Journal: JAMA Psychiatry (2019)

Boris D. Heifets, MD, PhD; Nolan R. Williams, MD; Brandon S. Bentzley, MD, PhD; Alan F. Schatzberg, MD
SAT0744-HPR Prevalence of commorbidities in patients with rheumatoid arthritis and correlation with disease activity and type of therapy
Authors: M. Cabrera, L. Villarreal, D. Buitrago-Garcia, P. Santos-Moreno
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rheumatoid arthritis (RA) is a common systemic autoimmune disease characterised chronic joint inflammation. Patients with RA are also reported to have higher prevalence of comorbidities such as cardiovascular disease, osteoporotic among others.<sup>1</sup> These comorbidities can be associated with higher mortality, poor life quality, and the increasing of costs for the health system. <h3>Objectives</h3> To describe the prevalence of comorbidities and characteristics of a Colombian population that assist to a RA specialised centre. <h3>Methods</h3> We performed a descriptive analysis; our main goal was to provide real-life data regarding characteristics of patients with RA. We collected sociodemographic information, DAS28, and prevalence of comorbidities regarding hypertension, cerebrovascular disease, diabetes mellitus, osteoporosis, renal chronic disease, or Sjogren's syndrome. We calculated means, and standard deviations for continuous variables and categorical variables were presented as rates. We estimated the prevalence of comorbidities and evaluate independent associations calculating prevalence ratios. <h3>Results</h3> 6376 patients were included in the analysis; mean age was 59 years±12, 81% were woman and 19% were men. Mean DAS28 was 2.8±1.07. From all patients the prevalence of comorbidities was 42% hypertension, cerebrovascular disease, diabetes mellitus, osteoporosis, renal chronic disease, or Sjogren's syndrome. Most of these patients 60% reported to have hypertension with any of the others comorbidities mentioned above, or osteoporosis with other comorbidities 46%. Regarding pharmacological therapy a higher proportion of patients received conventional DMARDs 90% see table 1. The prevalence of comorbidities was associated with sex and disease activity but did not have any association with pharmacological therapy see table 2. <h3>Conclusions</h3> As other studies conducted in Asian or Australian populations high blood pressure is the most common disease among patients with RA followed by osteoporosis(.<sup>1</sup> Sex is associated with higher comorbidities. According to these results it is important to consider the patient's context, medical conditions, and the number of comorbidities in order to understand the complexity of the management of patient with RA. <h3>Reference</h3> [1] Jin S, Li M, Fang Y, Li Q, Liu J, Duan X, et al. Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis. Arthritis research &amp; therapy2017;19(1):251. <h3>Disclosure of Interest</h3> None declared
THU0165 Obesity as one of the commodities was the robustest prediction factors for post therapeutic clinical remission of rheumatoid arthritis with short disease duration – results from kansai consortium for well-being of rheumatic disease patients
Authors: K. Murakami, M. Hashimoto, K. Murata, W. Yamamoto, R. Hara, M. Katayama, A. Ohnishi, K. Akashi, S. Yoshida, K. Nagai, Y. Son, H. Amuro, T. Hirano, K. Ebina, K. Nishitani, M. Tanaka, H. Ito, K. Ohmura, T. Mimori
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> A part of rheumatoid arthritis (RA) patients are resistant to clinical remission (CR) irrespective of therapies. In addition to known risk factors, systemic organ complications are assumed to interfere with CR. <h3>Objectives</h3> To extract the predictive comorbidities of clinical response of disease activities. <h3>Methods</h3> In Kansai consortium for well-being of rheumatic disease patients (ANSWER) cohort, which was the real world cohort of clinical database of rheumatic diseases, RA patients within 3 years of disease duration were included and followed. Using logistic regression analysis, background factors at the initial visit were extracted in order to predict CR after 1 year (1 year-non CR). <h3>Results</h3> 651 patients met in the inclusion criteria were under the analysis. Of those, 245 (37.6%) cases were resulted in 1 year-non CR. The average scores of DAS28-CRP at first visit and one year later was 3.51 and 2.02, respectively. Logistic regression analysis revealed that DAS28-CRP at first visit (OR 1.42/unit, 95% CI 1.24–1.63), concomitant use of methotrexate (MTX) or biologic disease modifying rheumatic drugs (bDMARDs) (OR 2.04, 95% CI 1.41–2.96) and body mass index (BMI) (OR 1.07/unit, 95% CI 1.02–1.12) were significant predictive factors of 1 year-non CR, but not in the case with gender, age, disease duration, hypertension, diabetes, dyslipidemia, lung diseases, heart diseases, digestive tissue diseases, history of malignancy nor concomitant autoimmune diseases. Using propensity score matching (1:1) stratified by gender, age, disease duration, concomitant use of MTX or bDMARDs and DAS28-CRP at baseline, the 49 pairs were matched between obese (defined as body mass index (BMI) over than 28) and non-obese patients. In these cohort, mean score of DAS28-CRP after 1 year was significantly higher in obese patients than in non-obese patients (2.63 and 2.18, respectively, see the figure 1). <h3>Conclusions</h3> In these early arthritis cohort, obese patients tend to remain higher disease activities even considering with gender, age and therapeutic management, although validation studies should be added to confirm these findings. <h3>Acknowledgements</h3> None. <h3>Disclosure of Interest</h3> None declared
AB1269 Quality standard for the management of patients with psoriatic arthritis: quantum project
Authors: T. Oton, E. Loza, E. Beltrán, C. Díaz-Miguel, C. Fernández-Carballido, E. Galíndez, C. García Porrua, J. Gratacós, J. Medina, R. Queiro, J. Ramírez, D. Reina, C. Rodríguez-Lozano, F. Rodríguez Martínez, E. Rubio, R. Veroz, J. Sanz Sanz
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> In the context of complex diseases like psoriatic arthritis (PsA), in which patients are often followed by different professionals, it is important for health professionals, providers and patients to have tools for delivering and demanding optimal care. One way to organise and evaluate health care quality is by the use of validated standards of care and quality indicators. <h3>Objectives</h3> To develop nationally accepted standards of care and quality indicators for care in PsA. <h3>Methods</h3> Qualitative methodology was followed that included: 1)Two focus groups (one with patients with PsA and another with non-rheumatologists specialists involved in the care of patients with PsA; 2) A narrative literature review of published documents related to the quality of care in PsA (including the QUANTUM Report<sup>1</sup>); 3) A nominal group meeting in which 15 expert rheumatologists generated and consensuated, a series of quality criteria as well as formulas or quantifiable objective measures to evaluate them; 4) A Delphi to establish the feasibility, priority and agreement with the quality criteria; 5) A final generation of standards of care and their attributes (including quality indicators). A descriptive analysis of the results was carried out. <h3>Results</h3> A total of 59 standards of care were generated, 19 of mandatory compliance, grouped into 4 blocks according to specific objectives: 1) Early diagnosis (n=6); 2) optimising the management of the disease (n=26), 3) multidisciplinary collaboration (n=9); 4) monitoring improvement (n=18). To assess the compliance of these standards of care, in many cases the medical records will be reviewed. Other sources will be the memory of the service and hospital and bibliographic databases. Regarding to the level compliance, for some of the standards of care this is yes/no, for others the compliance will range are from 50% to 100%, and in this range for many this will be by 80%. <h3>Conclusions</h3> This set of standards of care should help improve quality of care in APs patients. <h3>Reference</h3> [1] Favier G, Gladman DD, Merola JF, Armstrong AW, Boehncke WH, Helliwell PS. Benchmarking Care in Psoriatic Arthritis – The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting. J Rheumatol. 2017;44(5):674–8. <h3>Disclosure of Interest</h3> None declared
THU0265 Patients with axial spondyloarthritis rarely have 1 or 2 inflammatory back pain parameters
Authors: M. de Hooge, G.V. Varkas, D. Elewaut, F. van den Bosch
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The Berlin Algorithm is a tool that assists clinicians in diagnosing axial spondyloarthritis (axSpA). In the modified Berlin Algorithm inflammatory back pain (IBP) is excluded as entry criterion. Although the modified Berlin Algorithm is used in clinical practice some argue that this modification insufficiently emphasises the inflammatory character of axSpA. <h3>Objectives</h3> The study aim was to provide an overview of the IBP parameters present in axSpA patients included in the Be-Giant cohort. <h3>Methods</h3> Data of an observational multicentre cohort study was used. Patients aged ≥18 years with a new axSpA diagnosis and fulfilling the ASAS axSpA criteria were included in the Belgian inflammatory arthritis and spondylitis cohort (Be-Giant). All 5 IBP parameters used in the ASAS axSA classification criteria were collected during the clinical visit to the outpatient clinic. IBP parameters collected were: 1) Age at onset &lt;40 years, 2) insidious onset, 3) improvement with exercise, 4) no improvement with rest and 5) pain at night. IBP is defined when≥4 of these parameters are present. Besides these 5 parameters also 'alternating buttock pain' and 'morning stiffness' are reported as these parameters are part of other IBP criteria then the ASAS criteria. All descriptive data was presented as n (%) or means (±SD). <h3>Results</h3> All IBP parameters were collected from 228 patients and 49.6% (n=113) was male with mean age of 34.7 years (SD 9.7). Individual parameters were present in &gt;75% of the patients; the parameter 'age at onset &lt;40 years' was present in 95.2%, 'insidious onset' in 89%, 'improvement with exercise' in 86%, 'no improvement with rest' in 81.6% and 'pain at night' in 75.9% of the patients. There were 83 patients (36.4%) with alternating buttock pain and 173 patients (75.9%) with morning stiffness. More than 80% of the patients (183/228) had IBP according to the ASAS criteria as they had ≥4 IBP parameters. Patients rarely had 1 or 2 IBP parameters; 2 (0.9%) patients with 1 parameter and 12 (5.3%) patients with 2 parameters (table 1). <h3>Conclusions</h3> The majority of early axSpA patients had ≥4 IBP parameters and therefore fulfilled the ASAS IBP criteria. A minority shows 1 or none IBP parameter. Hence, the inflammatory character of axSpA does not seem to subverted now that IBP is not a mandatory feature in classification of axSpA. <h3>Disclosure of Interest</h3> None declared
THU0664 Treatment adherence to conventional and biologic disease modifying antirheumatic drugs in patients with rheumatoid arthritis
Authors: C.H. Feldman, J. Lii, C. Gopalakrishnan, J.M. Franklin, S.C. Kim
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> While treatment with conventional or biologic disease-modifying antirheumatic drugs (DMARDs) is highly effective in preventing radiographic progression and improving long-term functional outcome among patients with rheumatoid arthritis (RA), patient adherence to DMARD treatment is required for these positive effects. Suboptimal medication adherence has been repeatedly noted in patients with chronic medical conditions including RA. <h3>Objectives</h3> To examine patient adherence to different DMARDs for RA in a real-world setting. <h3>Methods</h3> We conducted a population-based cohort study using claims data from a US commercial health plan (Optum Clinformatics<sup>TM</sup> Datamart 2004–2015) and Medicaid (2000–2010). Eligible patients were those aged between 18 and 65 years and had at least two visits, 7–365 days apart, coded for RA (ICD-9: 714.xx). We then identified patients who newly started a conventional or biologic DMARD. The index date was the first dispensing date of conventional or biologic DMARDs after a 12 month continuous enrollment period. We examined patient demographics, clinical characteristics and health care utilisation factors specific to DMARDs types and their adherence to conventional or biologic DMARDs. All patients were required to be continuously enrolled for at least 1 year after the index date. Patients' adherence to each DMARD was measured using the proportion of days covered (PDC) calculated as the number of days suppled divided by 365 days post-index. <h3>Results</h3> We identified a total of 77,999 RA patients (37 018 in Optum and 40 981 in Medicaid) who started a conventional or biologic DMARD. Of those, 28 332 initiated methotrexate, 27 157 hydroxychloroquine, 6505 sulfasalazine, 2773 leflunomide and 19 381 biologic DMARDs. Table 1 shows patients' adherence specific to DMARD types. Overall, adherence was better in patients enrolled in Optum (i.e., a commercial health plan) than Medicaid. Except for infliximab given only intravenously, the PDC for the 1 year after initiating a conventional or biologic DMARD ranged from 30.99% (sulfasalazine in Medicaid) to 60.84% (abatacept in Optum). <h3>Conclusions</h3> In this large population-based cohort of RA patients enrolled in a commercial health plan or Medicaid, the 1 year medication adherence is generally low regardless of type of DMARDs. While adherence is better in the commercial health plan cohort than Medicaid, other factors predicting medication adherence need to be determined further. There is a strong need for future research examining the impact of medication adherence on long-term RA-related clinical outcomes. <h3>Disclosure of Interest</h3> C. Feldman: None declared, J. Lii: None declared, C. Gopalakrishnan: None declared, J. Franklin: None declared, S. Kim Grant/research support from: Pfizer, Bristol Myers Squibb, Roche
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study.
Authors: Aleksandar Sekulic, Michael Robert Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Fernando Quevedo, Jeannie Hou, Mukta Tripathi, Dirk Schadendorf
Journal: Journal of Clinical Oncology (2014)

9013 Background: BCC pathogenesis involves abnormal Hedgehog pathway (HP) signaling. In the ERIVANCE BCC trial, vismodegib (VISMO), the first FDA-approved HP inhibitor (HPI), showed objective response rates (ORRs) by independent review of 30% in metastatic (m) BCC and 43% in locally advanced (la) BCC, with median duration of response (DOR) of 7.6 mo for both. ORRs by investigator (INV) review were 45% (mBCC) and 60% (laBCC), with median DOR of 12.9 and 7.6 mo, respectively. Some patients (pts) continued VISMO treatment >3 yrs after start of therapy. We present safety and INV-assessed efficacy results 30 mo (30 May 2013) after primary analysis (26 Nov 2010). Methods: ERIVANCE BCC was a multicenter, international, nonrandomized study in pts (N=104) with radiographically measurable mBCC or laBCC (surgery inappropriate due to multiple recurrence, or substantial morbidity or deformity anticipated) receiving oral VISMO 150 mg daily until disease progression or intolerable toxicity. Key secondary endpoints included INV-ORR, progression-free survival (PFS), DOR, overall survival (OS), and safety. Results: At data cutoff, 9 pts (9%) continued to undergo protocol-specified assessments and 69 pts (66%) were in survival follow-up. ORR (INV) was 48.5% (mBCC) and 60.3% (laBCC), comparable with primary analysis. Median DOR (INV) improved from 12.9 and 7.6 mo for mBCC and laBCC (primary analysis) to 14.8 and 26.2 mo, respectively. Median (95% CI) PFS was 9.3 (7.4-16.6) and 12.9 (10.2-28.0) mo in mBCC and laBCC, respectively; median OS for mBCC was 33.4 (18.1-not estimable) mo and not reached in laBCC. Adverse events (AEs) remained consistent with the primary analysis; >30% of pts reported muscle spasm, alopecia, dysgeusia, weight decrease, fatigue, and nausea. 23 (22.1%) pts reported AEs leading to treatment discontinuation. 17 deaths (mBCC=10; laBCC=7) have been reported since the primary analysis and were not considered drug related. 16 deaths occurred in survival follow-up; 1 pt died due to general deterioration of health. Conclusions: The 30-month ERIVANCE BCC update confirmed the efficacy of the primary analyses and showed long-term consistent safety of VISMO in pts with aBCC. Clinical trial information: NCT00833417.